Clinical trial NCT03019549
Conditions: Healthy
Sponsor: AstraZeneca
Start date: 2017-01-12; Completion date: 2017-05-22
Enrollment: 42 participants; Allocation: NON_RANDOMIZED; Intervention model: CROSSOVER

Brief summary:
The purpose of this study is to evaluate the effect of lanabecestat on rosuvastatin. The amount of rosuvastatin in the blood will be compared, when taken alone, and then when taken with lanabecestat. The amount of lanabecestat that gets into the bloodstream will be measured. Information about any side effects that may occur will also be collected.

Participants will be on study for 21 days with a follow-up at least 7 days afterwards.

Screening will be undertaken within 45 days prior to enrollment.

Detailed description:

Arms: arm 1: Period 1: 20 mg rosuvastatin administered once orally (PO) arm 2: Period 2: 50 mg Lanabecestat (LY3314814) administered orally (PO) Day 1 to Day 12 Rosuvastatin: 20 mg co-administered PO on Day 8
Interventions: intervention 1: Lanabecestat intervention 2: Rosuvastatin
Intervention descriptions: intervention 1: Administered orally intervention 2: Administered orally

Protocol documents:
Prot_001.pdf: 
Protocol I8D-MC-AZEB(a) 
 
Effect of LY3314814 on the Pharmacokinetics of Rosuvastatin in Caucasian Healthy Subjects 
 
NCT03019549 
 
Approval Date: 21-October-2016 


I8D-MC-AZEB(a) Clinical Pharmacology Protocol
Page 1
LY3314814
Protocol I8D-MC-AZEB(a)
Effect of LY3314814 on the Pharmacokinetics of 
Rosuvastatin in Caucasian Healthy Subjects
Confidential Information
The information contained in this protocol is confidential and is intended for the use of 
clinical investigators.  It is the property of Eli Lilly and Company or its subsidiaries and 
should not be copied by or distributed to persons not involved in the clinical investigation of 
LY3314814, unless such persons are bound by a confidentiality agreement with Eli Lilly 
and Company or its subsidiaries.
Note to Regulatory Authorities:  This document may contain protected personal data 
and/or commercially confidential information exempt from public disclosure.  Eli Lilly and 
Company requests consultation regarding release/redaction prior to any public release.  In 
the United States, this document is subject to Freedom of Information Act (FOIA) 
Exemption 4 and may not be reproduced or otherwise disseminated without the written 
approval of Eli Lilly and Company or its subsidiaries.  
LY3314814
Eli Lilly and Company
Indianapolis, Indiana USA 46285
Clinical Pharmacology Protocol Electronically Signed and Approved by Lilly:  
21 October 2016
Amendment (a) Electronically Signed and Approved by Lilly
on approval date provided below.
Approval Date: 15-Mar-2017 GMT


I8D-MC-AZEB(a) Clinical Pharmacology Protocol
Page 2
LY3314814
Table of Contents
Effect of LY3314814 on the Pharmacokinetics of 
Rosuvastatin in Caucasian Healthy Subjects
Section
Page
Protocol I8D-MC-AZEB(a) Effect of LY3314814 on the 
Pharmacokinetics of Rosuvastatin in Caucasian Healthy Subjects .......................................1
Table of Contents........................................................................................................................2
1.
Protocol Synopsis................................................................................................................8
2.
Schedule of Activities .......................................................................................................10
3.
Introduction ......................................................................................................................15
3.1.
Study Rationale............................................................................................................15
3.2.
Background..................................................................................................................16
LY3314814 Clinical Experience ..........................................................................16
3.2.1.
3.2.1.1.
Clinical Pharmacokinetic Data........................................................................16
3.2.1.2.
Clinical Safety Data........................................................................................17
Rosuvastatin Clinical Safety Data ........................................................................17
3.2.2.
3.3.
Benefit/Risk Assessment..............................................................................................17
4.
Objectives and Endpoints..................................................................................................19
5.
Study Design.....................................................................................................................20
5.1.
Overall Design .............................................................................................................20
5.2.
Number of Participants.................................................................................................21
5.3.
End of Study Definition ...............................................................................................21
5.4.
Scientific Rationale for Study Design...........................................................................21
5.5.
Justification for Dose ...................................................................................................22
6.
Study Population...............................................................................................................23
6.1.
Inclusion Criteria..........................................................................................................23
6.2.
Exclusion Criteria ........................................................................................................24
6.3.
Lifestyle and/or Dietary Requirements .........................................................................26
Meals and Dietary Restrictions.............................................................................26
6.3.1.
Caffeine, Alcohol, and Tobacco ...........................................................................27
6.3.2.
Activity................................................................................................................27
6.3.3.
6.4.
Screen Failures.............................................................................................................27
7.
Treatment..........................................................................................................................28
7.1.
Treatment Administered...............................................................................................28
Packaging and Labeling .......................................................................................28
7.1.1.


I8D-MC-AZEB(a) Clinical Pharmacology Protocol
Page 3
LY3314814
7.2.
Method of Treatment Assignment ................................................................................28
Selection and Timing of Doses.............................................................................29
7.2.1.
7.3.
Blinding .......................................................................................................................29
7.4.
Dose Modification........................................................................................................29
7.5.
Preparation/Handling/Storage/Accountability...............................................................29
7.6.
Treatment Compliance .................................................................................................29
7.7.
Concomitant Therapy...................................................................................................29
7.8.
Treatment after the End of the Study............................................................................29
8.
Discontinuation Criteria ....................................................................................................30
8.1.
Discontinuation from Study Treatment.........................................................................30
Discontinuation of Inadvertently Enrolled Subjects ..............................................30
8.1.1.
8.2.
Discontinuation from the Study....................................................................................30
8.3.
Subjects Lost to Follow-up...........................................................................................31
9.
Study Assessments and Procedures ...................................................................................32
9.1.
Efficacy Assessments...................................................................................................32
9.2.
Adverse Events ............................................................................................................32
Serious Adverse Events........................................................................................33
9.2.1.
9.2.1.1.
Suspected Unexpected Serious Adverse Reactions..........................................33
Complaint Handling.............................................................................................34
9.2.2.
9.3.
Treatment of Overdose.................................................................................................34
9.4.
Safety...........................................................................................................................34
Laboratory Tests ..................................................................................................34
9.4.1.
Vital Signs ...........................................................................................................34
9.4.2.
Electrocardiograms ..............................................................................................35
9.4.3.
Physical Examination...........................................................................................35
9.4.4.
Body Weight........................................................................................................35
9.4.5.
Columbia-Suicide Severity Rating Scale ..............................................................35
9.4.6.
Safety Monitoring ................................................................................................36
9.4.7.
9.5.
Pharmacokinetics .........................................................................................................36
Bioanalysis...........................................................................................................37
9.5.1.
9.6.
Pharmacodynamics ......................................................................................................37
9.7.
Genetics .......................................................................................................................37
9.8.
Biomarkers...................................................................................................................37
9.9.
Health Economics ........................................................................................................38
10.
Statistical Considerations and Data Analysis .....................................................................39
10.1. Sample Size Determination ..........................................................................................39
10.2. Populations for Analyses..............................................................................................39
Study Participant Disposition ...............................................................................39
10.2.1.


I8D-MC-AZEB(a) Clinical Pharmacology Protocol
Page 4
LY3314814
Study Participant Characteristics ..........................................................................39
10.2.2.
10.3. Statistical Analyses ......................................................................................................39
Safety Analyses....................................................................................................40
10.3.1.
10.3.1.1.
Clinical Evaluation of Safety ..........................................................................40
10.3.1.2.
Statistical Evaluation of Safety .......................................................................40
Pharmacokinetic Analyses....................................................................................40
10.3.2.
10.3.2.1.
Pharmacokinetic Parameter Estimation...........................................................40
10.3.2.2.
Pharmacokinetic Statistical Inference .............................................................40
Interim Analyses ..................................................................................................41
10.3.3.
11.
References ........................................................................................................................42


I8D-MC-AZEB(a) Clinical Pharmacology Protocol
Page 5
LY3314814
List of Tables
Table
Page
Table AZEB.1.
Objectives and Endpoints .......................................................................19
Table AZEB.2.
Treatments Administered........................................................................28


I8D-MC-AZEB(a) Clinical Pharmacology Protocol
Page 6
LY3314814
List of Figures
Figure
Page
Figure AZEB.1.
Illustration of study design for Protocol I8D-MC-AZEB.........................20


I8D-MC-AZEB(a) Clinical Pharmacology Protocol
Page 7
LY3314814
List of Appendices
Appendix
Page
Appendix 1.
Abbreviations and Definitions ................................................................44
Appendix 2.
Clinical Laboratory Tests........................................................................47
Appendix 3.
Study Governance, Regulatory, and Ethical Considerations....................48
Appendix 4.
Hepatic Monitoring Tests for Treatment-Emergent Abnormality ............51
Appendix 5.
Blood Sampling Summary......................................................................52
Appendix 6.
Protocol Amendment I8D-MC-AZEB(a) Summary
Effect of LY3314814 on the Pharmacokinetics of Rosuvastatin in 
Caucasian Healthy Subjects....................................................................53


I8D-MC-AZEB(a) Clinical Pharmacology Protocol
Page 8
LY3314814
1. Protocol Synopsis
Title of Study:
Effect of LY3314814 on the Pharmacokinetics of Rosuvastatin in Caucasian Healthy Subjects
Rationale:  
Rosuvastatin is a breast cancer resistance protein (BCRP; also known as ABCG2) substrate that is sensitive to BCRP 
activity in the gastrointestinal tract and liver.  In vitro, LY3314814 has been characterized as a BCRP substrate and 
inhibitor.  This study uses rosuvastatin as a substrate to evaluate whether LY3314814 is an inhibitor of BCRP 
activity in vivo.
Objectives/Endpoints:  
Objectives
Endpoints
Primary
The primary objective is to evaluate the effect of 
LY3314814 on the pharmacokinetics (PK) of 
rosuvastatin in healthy subjects.
The primary endpoint is the area under the drug 
concentration-time curve (AUC) from zero to infinity 
(AUC[0-∞]) of rosuvastatin administered alone and 
with LY3314814.
Secondary
The secondary objectives are:  
To assess the safety of LY3314814 when 
coadministered with rosuvastatin in healthy subjects;
To determine the effect of rosuvastatin on the PK of 
LY3314814.
Secondary endpoints include:  
Incidence of treatment-emergent adverse events 
(TEAEs) and serious adverse events (SAEs);
PK parameters of LY3314814 administered alone 
and with rosuvastatin:  Cmax, tmax, and AUC during 
a 24-hour dosing interval (AUCτ).
Summary of Study Design:  
Study I8D-MC-AZEB is a Phase 1, open-label, fixed-sequence, 2-period crossover study in Caucasian healthy male 
subjects and female subjects not of childbearing potential.  Healthy males and females are as determined by medical 
history, physical examination, vital signs, clinical laboratory tests, and safety electrocardiograms.  Subjects are to be 
18 to 65 years of age, inclusive, with a body mass index between 19 and 32 kg/m2, inclusive, at screening.  Subjects 
with c.34AA, c.421AA, or c.34GA/ 421CA as well as c.521TC and c.521CC genotypes will be excluded from this 
study.  Eligible subjects must lack evidence of significant active or previous neuropsychiatric disease, assessed by 
medical history, physical examination, and Columbia-Suicide Severity Rating Scale (C-SSRS).  
Treatment Arms and Duration:  
Subjects will receive a single oral dose of 20 mg rosuvastatin on Period 1 Day 1.  In Period 2, subjects will receive 
oral doses of 50 mg LY3314814 once daily on Days 1 to 12 with a single 20-mg rosuvastatin oral dose 
coadministered on Day 8.
Number of Subjects:  
Up to 42 subjects may be enrolled in order that 24 subjects complete the study.


I8D-MC-AZEB(a) Clinical Pharmacology Protocol
Page 9
LY3314814
Statistical Analysis:  
Pharmacokinetic:  Rosuvastatin administered alone (Period 1 Day 1) will represent the reference treatment and 
rosuvastatin coadministered with LY3314814 will represent the test treatment (Period 2 Day 8) for rosuvastatin PK 
analysis.  Pharmacokinetic parameter estimates will be evaluated to delineate the effects of LY3314814 on 
rosuvastatin PK.  Log-transformed AUC(0-∞) and Cmax estimates for rosuvastatin will be analyzed using a linear 
mixed-effects analysis of variance model with treatment as a fixed effect and subject as a random effect.  The ratios 
of geometric least squares means (ie, rosuvastatin + LY3314814 to rosuvastatin alone) will be calculated along with 
the 90% confidence interval (CI) for the ratios.  The tmax for rosuvastatin will be analyzed using a nonparametric 
method; median differences of rosuvastatin + LY3314814 to rosuvastatin alone and the 90% CI for the median of 
differences will be calculated.  A similar analysis will be performed to evaluate the effect of rosuvastatin on 
LY3314814, where LY3314814 administered alone (Period 2 Day 7) will be the reference treatment and 
LY3314814 coadministered with rosuvastatin will remain the test treatment (Period 2 Day 8).  Additional analysis 
may be conducted if deemed appropriate.
Safety:  All investigational product and protocol procedure adverse events will be listed, and if the frequency of 
events allows, safety data will be summarized using descriptive methodology.  The incidence of symptoms for each 
treatment will be presented by severity and by association with investigational product as perceived by the 
investigator.  Each symptom will be classified by the most suitable term from the medical regulatory dictionary.  
The number of investigational product-related SAEs will be reported.  Safety parameters that will be assessed 
include safety clinical laboratory parameters, vital signs, and C-SSRS.  Orthostatic changes in vital signs will be 
assessed using change from supine to standing.  The clinical laboratory parameters and C-SSRS data will be listed.  
Vital signs will be listed and summarized using standard descriptive statistics.  Electrocardiograms will be 
performed for safety monitoring purposes and will not be presented.  Additional analysis may be performed if 
warranted upon review of the data.


I8D-MC-AZEB(a) Clinical Pharmacology Protocol
Page 10
LY3314814
2. Schedule of Activities


I8D-MC-AZEB(a) Clinical Pharmacology Protocol
Page 11
LY3314814
Study Schedule Protocol I8D-MC-AZEB
Period 1
Screening
Period 1
Comments
Procedure
Up to 45 days 
prior to 
enrollment
Day
-1
1
2
3
4
5
6
Outpatient Visit
X
Subject Admission to 
CRU
X
Informed Consent
X
Medical History
X
Height and BMI
X
Weight
X
X
Drug and Alcohol Tests
X
X
C-SSRS
X
X
Estimated GFR
X
Estimated GFR will be calculated using the CKD-EPI equation.
Physical Exam
X
After screening exam on Period 1 Day -1, exams are to include only
medical review and targeted examination, as appropriate.
Pregnancy Test
X
Pregnancy tests will be performed for all females.  
Vital Signs (supine and 
orthostatic) (hours) a
X
P, 4,
8, 12
24
X
X
X
X
Vital signs include blood pressure and pulse rate.  Body temperature will 
be obtained at screening and as clinically indicated.  Sampling times are 
relative to the time of rosuvastatin administration (0 hour).  Additional 
vital signs may be measured during each study period, if clinically 
indicated.
Clinical Lab Tests
X
X
X
See Appendix 2 for details.  Results from sample on Period 1 Day -1 will 
be reviewed by the investigator prior to dosing on Period 1 Day 1.  Tests 
may be repeated at the investigator’s discretion.
OATP1B1,
OATP521 T/TT, and 
BCRP Genotypes
X
Genotypes will be used to confirm subject eligibility.  Subjects who meet 
all other screening eligibility criteria will return for a second screening 
visit, at least 21 days prior to enrollment, when samples will be collected 
for genotype analysis.
12-lead ECG
X
X
Additional ECGs may be obtained as clinically indicated.  
Genetic Sample
P
Single sample for pharmacogenetic analysis.


I8D-MC-AZEB(a) Clinical Pharmacology Protocol
Page 12
LY3314814
Screening
Period 1
Comments
Procedure
Up to 45 days 
prior to 
enrollment
Day
-1
1
2
3
4
5
6
Rosuvastatin 
Administration
X
Rosuvastatin PK 
Samples (hours) a
P, 1, 
2, 3, 
4, 5, 
6, 8, 
12
24
48
72
96
120
Sampling times are relative to the time of rosuvastatin administration 
(0 hour).  
Biomarker Samples
(hours) a
P, 1, 
2, 3, 
4, 5, 
6, 8, 
12
24
48
72
96
120
Samples for non-pharmacogenetic biomarker analysis.
AE Assessment
X
X
Abbreviations:  AE = adverse event; BCRP = breast cancer resistance protein; BMI = body mass index; CKD-EPI = Chronic Kidney Disease Epidemiology 
Collaboration; CRU = clinical research unit; C-SSRS = Columbia-Suicide Severity Rating Scale; ECG = electrocardiogram; GFR = glomerular filtration rate; 
OATP = organic anion transporting polypeptide; P = predose; PK = pharmacokinetics.  
a
Specified times are approximate and actual times will be recorded.  Actual sampling time should not exceed 1 hour prior to dosing for the predose sample or 
±10% of the specified postdose sample time.  


I8D-MC-AZEB(a) Clinical Pharmacology Protocol
Page 13
LY3314814
Study Schedule Protocol I8D-MC-AZEB 
Period 2
Period 2
Discharge/
Follow-up
Comments
Procedure
Day
≥7 days after 
final dose or 
ED
-1
1
2
3 
to 
5
6
7
8
9
10
11
12
13
Outpatient Visit
X
Subject Discharge 
from CRU
X
Weight
X
C-SSRS
X
X
X
Physical Exam
X
After screening exam on Period 1 Day -1, exams 
are to include only medical review and targeted 
examination, as appropriate.
Pregnancy Test
X
Pregnancy tests will be performed for all
females.
Vital Signs 
(supine and 
orthostatic) 
(hours) a
P, 4, 8, 
12
24
P, 4,
8, 12
24
X
X
X
X
X
Vital signs include blood pressure and pulse rate.  
Body temperature will be obtained as clinically 
indicated.  Sampling times are relative to the 
time of study drug administration (0 hour).  
Additional vital signs may be measured, if 
clinically indicated.
Clinical Lab Tests
X
X
X
See Appendix 2 for details.  Results from sample 
on Period 1 Day 6 will be reviewed by the 
investigator prior to dosing on Period 2 Day 1.  
Tests may be repeated at the investigator’s 
discretion.  
12-lead ECG
X
X
X
Additional ECGs may be obtained if clinically 
indicated.  
Rosuvastatin 
Administration
X
LY3314814 and rosuvastatin will be 
co-administered at the same time.


I8D-MC-AZEB(a) Clinical Pharmacology Protocol
Page 14
LY3314814
Period 2
Discharge/
Follow-up
Comments
Procedure
Day
≥7 days after 
final dose or 
ED
-1
1
2
3 
to 
5
6
7
8
9
10
11
12
13
LY3314814 
Administration
X
X
X
X
X
X
X
X
X
X
Rosuvastatin PK 
Samples (hours) a
P, 1, 
2, 3, 
4, 5, 
6, 8, 
12
24
48
72
96
120
Sampling times are relative to the time of 
rosuvastatin administration (0 hour).  Samples 
may be collected at ED as applicable.
LY3314814 PK 
Samples (hours) a
P, 
0.5, 
1, 2, 
3, 4,
8, 12
P, 
0.5, 
1, 2, 
3, 4, 
8, 12
P
Sampling times are relative to the time of 
LY3314814 administration (0 hour).  Samples 
may be collected at ED as applicable.  
Biomarker 
Samples (hours) a
P, 1, 
2, 3, 
4, 5, 
6, 8, 
12
24
48
72
96
120
Samples for non-pharmacogenetic biomarker 
analysis.  Sampling times are relative to the time 
of rosuvastatin administration (0 hour).  Samples 
may be collected at ED as applicable.
AE Assessment
X
X
Abbreviations:  AE = adverse event; CRU = clinical research unit; C-SSRS = Columbia-Suicide Severity Rating Scale; ECG = electrocardiogram; ED = early 
discontinuation; P = predose; PK = pharmacokinetics.  
a
Specified times are approximate and actual times will be recorded.  Actual sampling time should not exceed 1 hour prior to dosing for the predose sample or 
±10% of the specified postdose sample time.


I8D-MC-AZEB(a) Clinical Pharmacology Protocol
Page 15
LY3314814
3. Introduction
3.1.
Study Rationale
The breast cancer resistance protein (BCRP; also known as ABCG2) is an efflux transporter 
located in the small intestine, colon, and liver canalicular membrane (among other tissues), 
serving to limit the absorption of drugs from the gastrointestinal tract and to increase biliary 
secretion of drugs and their metabolites (Maliepaard et al. 2001).  Certain BCRP substrates have 
been shown to have clinically significant drug interactions when administered with inhibitors of 
BCRP (International Transporter Consortium et al. 2010).  Many of the substrates of BCRP are 
also substrates for other transporters or metabolizing enzymes, making it difficult to elucidate the 
clinical relevance of a putative BCRP substrate.  A review by a consortium of pharmaceutical 
researchers recently suggested that oral rosuvastatin is likely the best available substrate to 
investigate the activity of a potential BCRP inhibitor, as its relatively low permeability makes it 
sensitive to BCRP activity in the gastrointestinal tract, and its relatively high biliary clearance 
make it sensitive to BCRP activity in the liver (Lee et al. 2015).  
Rosuvastatin is a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor indicated for 
patients with primary hyperlipidemia, among other conditions.  Rosuvastatin has a 
bioavailability of approximately 20%, reaching time of maximum observed drug concentration 
(tmax) approximately 3 to 5 hours after administration.  Rosuvastatin pharmacokinetics (PK) are 
not impacted by the time of dose administration.  Approximately 72% of total rosuvastatin 
clearance is hepatic, with the majority of this clearance occurring through biliary excretion; 
approximately 10% of an administered dose of rosuvastatin is metabolized.  This metabolism 
primarily occurs via cytochrome P450 (CYP) 2C9.  The half-life associated with the terminal 
elimination phase (t1/2) is approximately 19 hours.  Lee and colleagues (2015) note that 
rosuvastatin is a substrate for several transporters besides BCRP, including the hepatic uptake 
transporters organic anion transporting polypeptide (OATP) 1B1 and 1B3, as well as multidrug 
resistance associated protein 2 (also known as ABCC2; primarily involved in the efflux of drugs 
into bile or renal tubule).  Genetic polymorphisms are known to influence the activity of these 
transporters. For example, various genetic polymorphisms of BCRP are found in humans; 
notably the c.34G>A and c.421C>A single nucleotide polymorphisms (SNPs) are associated 
with impaired BCRP activity and significantly increased systemic exposure of rosuvastatin 
(Furukawa et al. 2009, Wan et al. 2015, Keskitalo et al. 2009).  Rosuvastatin area under the 
concentration-time curve (AUC) was 65% higher in carriers of the OATP1B1 (also known as 
SLCO1B1) c.521T>C SNP compared to subjects with the c.521TT genotype (Pasanen et al. 
2007, Niemi et al. 2011). The c.1249G>A SNP in ABCC2 has been associated with a 2-fold 
increase in deferasirox exposure, and may therefore be expected to impact rosuvastatin PK
(Cusato et al. 2015).  Unlike many other BCRP substrates, however, rosuvastatin is neither 
metabolized by CYP3A to a clinically significant extent, nor is it a substrate for P-glycoprotein 
(Pgp; Crestor Prescribing Information).  
LY3314814, also known as AZD3293, is a brain-permeable inhibitor of human beta-site amyloid 
precursor protein cleaving enzyme 1 being developed to slow disease progression in patients 
with early Alzheimer’s disease (AD).  In vitro, LY3314814 has been characterized as a BCRP 


I8D-MC-AZEB(a) Clinical Pharmacology Protocol
Page 16
LY3314814
substrate and inhibitor (concentration of drug causing half-maximal inhibitory effect
[IC50] = 11.1 M).  Immediately following oral administration of 50 mg LY3314814, drug 
concentrations in gastric fluid are anticipated to exceed the in vitro IC50, suggesting that there is 
a potential for inhibition at the level of the intestinal wall.  Once absorbed, however, steady-state 
maximum observed drug concentration (Cmax) following a regimen of 50 mg LY3314814 once 
daily (QD) (the highest dose being investigated in ongoing pivotal registration studies) is 
anticipated to be <10% of the IC50 for BCRP, suggesting a relatively low likelihood for 
LY3314814 to inhibit BCRP activity in other tissues.  Of note, while LY3314814 has also been 
found to inhibit OATP1B1 and OATP1B3 in vitro, the LY3314814 IC50 for these transporters 
was high (≥40 M), and unlikely to be clinically significant, as compared to BCRP.  In vitro 
studies have also demonstrated that LY3314814 is not an inducer or inhibitor of CYP2C9 and 
would, therefore, not be expected to alter the metabolism of rosuvastatin. Based upon these data, 
rosuvastatin appears to be a reasonably specific substrate to evaluate whether LY3314814 is an 
inhibitor of BCRP activity in vivo.
3.2.
Background
LY3314814 Clinical Experience
3.2.1.
As of 21 June 2016, approximately 411 subjects/patients have been exposed to LY3314814 in 
completed clinical studies, including 399 healthy subjects and 12 patients with mild to moderate 
AD.  Single doses ranging from 1 to 750 mg and multiple daily doses up to 150 mg were 
explored in the 10 completed clinical pharmacology studies.  Two Phase 3 clinical trials testing 
daily doses of 20 and 50 mg LY3314814 are ongoing to evaluate the clinical efficacy of 
LY3314814 in patients with early AD (ClinicalTrials.gov identifiers:  NCT02245737 and 
NCT02783573).  One additional Phase 1 study (food effect) has completed with no additional 
safety concerns.
3.2.1.1.
Clinical Pharmacokinetic Data
LY3314814 PK have been evaluated following single doses of 1 to 750 mg and at steady state 
from 15 to 150 mg.  Following oral dosing, LY3314814 tmax is approximately 1 to 2 hours 
postdose and then follows a bi-exponential elimination profile.  The LY3314814 t1/2 is 
approximately 18 hours.  Upon multiple dosing, exposure increases modestly with an 
accumulation ratio of approximately 1.46, based on area under the drug concentration-time curve 
(AUC).  Steady state appears to be achieved 4 to 8 days following the initiation of dosing, 
consistent with LY3314814 t1/2.  Over the dose range from 15 to 150 mg, the AUC of 
LY3314814 increases in a dose proportional manner, although Cmax appears to increase in a 
greater-than-proportional manner (a 3.3-fold increase in dose produced approximately a 4.2-fold 
increase in Css,max values).  No meaningful differences in PK have been observed between 
young and elderly healthy subjects, or between healthy subjects and patients with AD.  Renal 
clearance was approximately 1.0 to 1.5 L/h (roughly 5% to 10% of apparent total body 
clearance), suggesting that renal clearance is a minor elimination pathway.  LY3314814 is a 
substrate of CYP3A, as shown by drug interaction studies where strong inhibitors of CYP3A 
activity increased LY3314814 exposure by up to 2.85-fold.  While LY3314814 was shown to be 


I8D-MC-AZEB(a) Clinical Pharmacology Protocol
Page 17
LY3314814
a CYP3A inducer in vitro, clinical evidence suggests that there is no meaningful effect of 
LY3314814 on CYP3A activity. The effect of LY3314814 on Pgp activity has been studied in 
vitro and clinically.  In vitro studies demonstrate that LY3314814 is a substrate and an inhibitor 
of Pgp.  In clinical studies, LY3314814 increased dabigatran exposures by 15% when 
LY3314814 and dabigatran etexilate were administered at the same time, demonstrating that
LY3314814 is a relatively weak inhibitor of Pgp.  Since 21 June 2016, a food effect study was 
completed demonstrating that administration of 50 mg LY3314814 with food resulted in a 
modest (approximately17%) reduction in Cmax, although AUC was not impacted, suggesting that 
food reduces the rate, but not the extent of absorption.  The PK results for the major metabolite 
AZ13569724 mirrored those of the parent.
Additional information regarding LY3314814 PK may be found in the Investigator’s Brochure 
(IB).
3.2.1.2.
Clinical Safety Data
No clinically significant safety or tolerability concerns have been identified to date in the 
LY3314814 Phase 1 program up to the highest dose given (750-mg single dose; 150-mg daily 
dosing for up to 12 days).  Across all 10 of the studies completed as of 21 June 2016, 2 serious 
adverse events (SAEs) were reported in 2 patients (severe ventricular tachycardia in a patient 
with a previously undisclosed cardiomyopathy, and cellulitis).  Both SAEs occurred after 5 days 
of daily dosing and were judged by the investigator as not related to LY3314814.
The most frequent (occurring in 1% to 10% of healthy subjects) treatment-emergent adverse 
events (TEAEs) judged by the investigator to be related to study drug during LY3314814 
treatment include headache, orthostatic hypotension, dizziness, constipation, back pain, rash, dry 
skin, lip dry, diarrhea, nausea, dermatitis contact, pruritus, and somnolence.  The most common 
TEAEs judged by the investigator to be related to study drug in patients with mild to moderate 
AD include blurred vision, headache, and orthostatic hypotension.  No clinical laboratory or 
electrocardiogram (ECG) safety concerns have been identified in the completed Phase 1 studies.  
More information about the known and expected benefits, risks, and reasonably anticipated AEs 
may be found in the IB.  
Rosuvastatin Clinical Safety Data
3.2.2.
Full details of the known and expected benefits, risks, and reasonably anticipated AEs of 
rosuvastatin may be found the Crestor® Prescribing Information. The most frequent adverse 
reactions (rate >2%) are headache, myalgia, abdominal pain, asthenia, and nausea. Rosuvastatin 
may cause fetal harm when administered to a pregnant woman (Crestor Prescribing Information).
3.3.
Benefit/Risk Assessment
No clinically significant safety or tolerability concerns have been identified in subjects to date 
for LY3314814 up to the highest dose given (750-mg single dose; 150-mg daily dosing for up to 
12 days).  The risk profile of LY3314814 remains supportive of further clinical development.


I8D-MC-AZEB(a) Clinical Pharmacology Protocol
Page 18
LY3314814
Hypopigmentation:  Hypopigmentation of skin and haircoat has been observed in dogs.  In 
completed Phase 1 studies with up to 6 weeks duration of exposure to LY3314814, no clinically 
significant hypopigmentation has been reported.  Physical examinations and serial complete skin 
examinations will be performed by a dermatologist in clinical studies, as appropriate, and are 
defined in clinical protocols.  If hypopigmentation is observed, patients may continue treatment.
Retinal effects:  Adverse retinal changes were observed in preclinical studies, only at doses 
exceeding a maximum tolerated dose in rats (298-fold AUC-based multiple to 50-mg dose in 
humans).  Adverse retinal changes were also observed in dogs at only the high dose in the 
9-month study (211-fold AUC-based multiple to 50-mg dose in humans).  In study 
I8D-MC-AZEO, 1 subject receiving LY3314814 and warfarin was noted to have asymptomatic 
small dot retinal hemorrhages on follow-up examination that resolved without intervention.  
Based on the large safety margins to adverse effects, the risk of adverse retinal effects occurring 
at the intended clinical doses of LY3314814 (up to 50 mg) is considered to be low.  
Ophthalmologic examinations are not planned for this study.
LY3314814 may increase rosuvastatin exposure.  Crestor (rosuvastatin calcium) is marketed at 
doses up to 40 mg/day. Because this study is being conducted in healthy subjects who are not 
taking other drugs, and each subject will receive only a single dose of rosuvastatin on 2
occasions, a dose of 20 mg rosuvastatin is considered sufficient to appropriately characterize any 
potential drug-drug interaction, while minimizing any potential safety concerns that might be 
anticipated due to increased rosuvastatin exposure (Lee et al. 2015).  
In this study, there is no anticipated therapeutic benefit for the subjects.
More information about the known and expected benefits, risks, SAEs, and reasonably 
anticipated AEs of LY3314814 may be found in the IB.


I8D-MC-AZEB(a) Clinical Pharmacology Protocol
Page 19
LY3314814
4. Objectives and Endpoints
Table AZEB.1 shows the objectives and endpoints of the study.
Table AZEB.1.
Objectives and Endpoints
Objectives
Endpoints
Primary
The primary objective is to evaluate the effect of 
LY3314814 on the PK of rosuvastatin in healthy 
subjects.
The primary endpoint is AUC from zero to infinity 
(AUC[0-∞]) of rosuvastatin administered alone and with 
LY3314814.
Secondary
The secondary objectives are:  
To assess the safety of LY3314814 when 
coadministered with rosuvastatin in healthy subjects;
To determine the effect of rosuvastatin on the PK of 
LY3314814.
Secondary endpoints include:
Incidence of TEAEs and SAEs;
PK parameters of LY3314814 administered alone and 
with rosuvastatin:  Cmax, tmax, and AUC during a 
24-hour dosing interval (AUCτ).
Exploratory
The exploratory objective of this study is to evaluate the 
effect of genetic polymorphisms on the magnitude of the 
interaction between rosuvastatin and LY3314814.
Exploratory endpoints include key PK parameters of 
rosuvastatin:  Cmax, AUC(0-∞), and tmax.




I8D-MC-AZEB(a) Clinical Pharmacology Protocol
Page 21
LY3314814
concentrations.  Blood samples will be collected predose on Day 8 and up to 120 hours postdose
(Day 13) for measurement of plasma rosuvastatin concentrations.  Subjects will be discharged on 
Day 13 of Period 2 after all assessments have been completed. A follow-up visit will occur at 
least 7 days following the final LY3314814 dose in Period 2.
Safety and tolerability will be assessed throughout the study by means of vital sign 
measurements, clinical laboratory tests, ECGs, Columbia-Suicide Severity Rating Scale 
(C-SSRS), physical examinations (as indicated), and AE recording.
5.2.
Number of Participants
Up to 42 subjects may be enrolled so that approximately 24 subjects complete the study.
5.3.
End of Study Definition
End of the study is the date of the last visit or last scheduled procedure shown in the Schedule of 
Activities (Section 2) for the last subject.
5.4.
Scientific Rationale for Study Design
This study will be open-label. As the primary endpoints are objective rather than subjective,
investigators and subjects do not need to be blinded.
Oral administration of LY3314814 has been chosen as this is the intended clinical route of 
administration.  A fixed-sequence crossover design has been selected due to the long t1/2 of 
rosuvastatin and LY3314814 (19 and 18 hours, respectively), as an increased study duration 
would be required if a 2-sequence crossover design was selected.  The 7-day washout period 
after rosuvastatin administration in Period 1 is considered adequate to minimize potential PK 
carryover effects of rosuvastatin.  In Period 2, LY3314814 will be administered for 7 days to 
allow adequate time to reach steady state prior to coadministration with rosuvastatin.  Following 
coadministration, LY3314814 will continue to be administered QD during the rosuvastatin PK 
sample collection so any potential interaction due to LY3314814 can be determined.  Based upon 
the available clinical PK data for LY3314814, the duration of this study is considered adequate 
to achieve the study objectives.
The selection of healthy subjects is appropriate and in keeping with standard regional practices 
for clinical pharmacology studies.  The inclusion and exclusion criteria are chosen to select 
subjects who are known to be free from any significant illness and from any condition that could 
affect their safety or interfere with meeting the study objectives.  
The human BCRP transporter is polymorphic.  Subjects with the c.421C>A and c.34G>A
polymorphisms, specifically the c.34AA, c.421AA, and c.34GA/ 421CA genotypes, will be 
excluded because these genetic polymorphisms are associated with impaired BCRP activity
(Furukawa et al. 2009, Wan et al. 2015, Keskitalo et al. 2009). Because the activity of BCRP is 
impaired with these subjects, it would be anticipated that even complete inhibition of BCRP 
would not result in a substantial change in rosuvastatin exposure. Accordingly, excluding 
subjects with these polymorphisms will ensure that the “worst-case” interaction between 
LY3314814 and rosuvastatin will be evaluated in this study.


I8D-MC-AZEB(a) Clinical Pharmacology Protocol
Page 22
LY3314814
The human OATP1B1 transporter (also known as SLCO1B1) is also polymorphic. In order to 
evaluate worst-case interactions between LY3314814 and rosuvastatin, subjects with the 
c.521T>C polymorphism will be excluded from this study because this genetic polymorphism is 
associated with decreased transporting activity of OATP1B1 (Niemi et al. 2011) and higher 
plasma rosuvastatin concentrations (Crestor Prescribing Information).  
The rate of c.34G>A and c.421C>A polymorphisms tend to be lower in Caucasian subjects than 
many other racial groups (Kim et al. 2010).  Because of this, and due to other studies showing 
that rosuvastatin exposure in Asian subjects is approximately 2-fold that in Caucasian subjects
(Crestor Prescribing Information), participation in this study will be limited to Caucasian 
subjects.  
5.5.
Justification for Dose
A dose of 50 mg LY3314814 administered orally QD was selected based on current clinical 
study data.  LY3314814 doses up to 750 mg (highest planned dose) were well tolerated in the 
single ascending dose study.  Multiple LY3314814 doses up to 150 mg QD for 12 days were also
well tolerated.  The 50-mg dose of LY3314814 selected for this study is the highest dose that is 
being used in the ongoing Phase 3 studies, and is the highest planned dose in Phase 3 studies.
Rosuvastatin is commonly administered to adults at an oral dose of 5 to 40 mg QD, with the 
majority of the clinical drug-drug interaction or pharmacogenetic studies conducted using a 10-
or 20-mg dose (Crestor Prescribing Information; Lee et al. 2015). Rosuvastatin administered 
orally at a dose of 20 mg is suggested as a good clinical probe for both hepatic and intestinal 
BCRP function (Lee et al. 2015).  Coadministration of rosuvastatin with LY3314814 may 
increase rosuvastatin exposure.  Using calculations similar to those described by Elsby and 
colleagues (2016) and the assumption that LY3314814 will only inhibit BCRP in the intestine, it 
is estimated that LY3314814 may increase rosuvastatin exposures by approximately 70%.  The 
20-mg rosuvastatin dose selected for this study should provide adequate plasma rosuvastatin 
concentrations to address the study objectives with minimal risk for AEs.


I8D-MC-AZEB(a) Clinical Pharmacology Protocol
Page 23
LY3314814
6. Study Population
Eligibility of subjects for study enrollment will be based on the results of screening medical 
history, physical examination, vital signs, clinical laboratory tests, C-SSRS, and safety ECG.  
The nature of any conditions present at the time of the physical examination and any preexisting 
conditions will be documented.
Screening may occur up to 45 days prior to enrollment.  Subjects who are not enrolled within 
45 days of screening may be subjected to an additional medical assessment and/or clinical 
measurements to confirm their eligibility.  Subjects who meet all other screening eligibility 
criteria will return for a second screening visit, at least 21 days prior to enrollment, when 
samples will be collected for genotype analysis.  Genotyping only needs to be conducted once, 
regardless of the 45-day screening window and any repeated assessments to confirm eligibility.
Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as 
protocol waivers or exemptions, are not permitted.
6.1.
Inclusion Criteria
Subjects are eligible for inclusion in the study only if they meet all of the following criteria at 
screening and/or enrollment:
[1]
are overtly healthy males or females, as determined by medical history and 
physical examination
[1a] women not of childbearing potential may participate and include those who 
are:
A. infertile due to surgical sterilization (hysterectomy, bilateral 
oophorectomy, or tubal ligation), congenital anomaly such as mullerian 
agenesis; or
B. postmenopausal – defined as women over 50 years of age with an intact 
uterus who have not taken hormones or oral contraceptives within 
1 year, who have had either spontaneous cessation of menses for at least 
12 consecutive months, or 6 to 12 months of spontaneous amenorrhea 
with follicle-stimulating hormone level >40 mIU/mL consistent with 
menopause
[2]
are Caucasian and may be of Hispanic ethnicity
[3]
are 18 to 65 years old, inclusive, at the time of screening 
[4]
have a body mass index (BMI) of 19 to 32 kg/m2, inclusive, at the time of 
screening
[5]
have clinical laboratory test results within normal reference range for the 
investigative site, or results with acceptable deviations that are judged to be 
not clinically significant by the investigator
[6]
have venous access sufficient to allow for blood sampling as per the protocol


I8D-MC-AZEB(a) Clinical Pharmacology Protocol
Page 24
LY3314814
[7]
are reliable and willing to make themselves available for the duration of the 
study and are willing to follow study procedures
[8]
are able and willing to give signed informed consent
6.2.
Exclusion Criteria
Subjects will be excluded from study enrollment if they meet any of the following criteria at 
screening and/or enrollment:
[9]
are investigative site personnel directly affiliated with this study and their 
immediate families.  Immediate family is defined as a spouse, biological or 
legal guardian, child, or sibling.
[10] are Lilly employees, AstraZeneca employees, or Covance employees
[11] are currently enrolled in a clinical trial involving an investigational product or 
any other type of medical research judged not to be scientifically or medically 
compatible with this study  
[12] have participated, within the last 30 days, in a clinical trial involving an 
investigational product.  If the previous investigational product has a long 
half-life, 3 months or 5 half-lives (whichever is longer) should have passed.
[13] have previously completed or withdrawn from this study or any other study 
investigating LY3314814, and have previously received the investigational 
product 
[14] have known allergies to LY3314814, rosuvastatin, related compounds, or any 
components of the formulation, or history of significant allergic disease as 
determined by the investigator
[15] have a history of significant ophthalmic disease, which includes subjects with 
clinically significant eye abnormalities, particularly any eye problem 
involving the retina 
[16] have vitiligo or any other clinically significant disorder of skin pigmentation 
as determined by the investigator 
[17] have a history of previous or ongoing neuropsychiatric disease/condition 
including psychosis, affective disorder, anxiety disorder, borderline state, and 
personality disorder 
[18] have acute suicidality, as evidenced by answering “yes” for Question 4 or 
Question 5 on the C-SSRS, indicating active suicidal ideation with any intent 
to act, at screening, Check-in, or at Period 2 Day -1
[19] have a history of suicidal behavior such that a determination of “yes” is made 
on the Suicidal Behavior section of the C-SSRS for “Actual Attempt,” 
“Interrupted Attempt,” “Aborted Attempt,” or “Preparatory Acts or Behavior”
[20] have a history of neurologic disease, including seizures, or clinically 
significant head injury


I8D-MC-AZEB(a) Clinical Pharmacology Protocol
Page 25
LY3314814
[21] have a history of use of antipsychotic drugs, or chronic use of antidepressant 
or anxiolytic drugs, prescribed as well as non-prescribed use
[22] have an abnormality in the 12-lead ECG that, in the opinion of the 
investigator, increases the risks associated with participating in the study, or 
have a history of significant dysrhythmias or atrioventricular (AV) block 
(including first degree AV block).  
[23] have Fridericia-corrected QT interval of  >470 msec for females or >450 msec 
for males
[24] have a history of prolonged QT syndrome
[25] have a clinically significant abnormal blood pressure or heart rate (supine) as 
determined by the investigator
[26] have c.34AA, c.421AA, or c.34GA/ 421CA genotypes as determined by 
genotyping
[27] have c.521TC and c.521CC genotypes as determined by genotyping
[28] have estimated glomerular filtration rate ≤59 mL/min/1.73 m2
[29] have aspartate aminotransferase (AST) or alanine aminotransferase (ALT)
levels above the upper limit of normal (ULN) at screening or Check-in.  Tests 
may be repeated at the investigator’s discretion.    
[30] history of myopathy
[31] have any medical conditions, medical history, or are taking any medication 
which are contraindicated in the Crestor (rosuvastatin) Prescribing 
Information
[32] have a history of or current cardiovascular, respiratory, hepatic, renal, 
gastrointestinal, endocrine, hematological, or neurological disorders capable 
of significantly altering the absorption, metabolism, or elimination of drugs; 
of constituting a risk when taking the investigational product; or of interfering 
with the interpretation of data as determined by the investigator
[33] regularly use known drugs of abuse and/or show positive findings on urinary 
drug screening
[34] show evidence of human immunodeficiency virus (HIV) infection and/or 
positive HIV antibodies
[35] show evidence of hepatitis C and/or positive hepatitis C antibody
[36] show evidence of hepatitis B and/or positive hepatitis B surface antigen
[37] are women of childbearing potential or who are pregnant or lactating
[38] are currently or have been smokers or users of tobacco- or nicotine-containing 
products within the 3 months prior to Check-in


I8D-MC-AZEB(a) Clinical Pharmacology Protocol
Page 26
LY3314814
[39] have donated more than 500 mL of blood, including plasma and platelets, 
within 1 month prior to Check-in
[40] use of any drugs or substances that are known strong inducers or inhibitors of 
CYP3A.  Strong inhibitors of Pgp or inducers or inhibitors of BCRP are 
specifically excluded within 14 days prior to the first administration of study 
drug and during the study
[41] have used or intend to use any drug or dietary supplement that may affect 
rosuvastatin within 14 days prior to the first dose of rosuvastatin and/or during 
the conduct of the study
[42] have used or intend to use prescription medication, oral over-the-counter 
medication, or herbal preparations within 14 days prior to admission and 
during the study.  If this situation arises, inclusion of an otherwise suitable 
subject may be at the discretion of the investigator.
[43] are unwilling to comply with the dietary requirements/restrictions du ring the 
study:  (i) consume only the meals provided while resident in the CRU, and 
(ii) refrain from eating any food or drinking any beverages containing 
restricted foods, including grapefruits or grapefruit-containing products, 
Seville oranges or Seville orange-containing products, star fruits or star 
fruit-containing products, pomelo, or commercial apple juice or orange juice, 
within 7 days prior to the first dose of study drug until the final PK sample is 
collected
[44] unwilling to refrain from strenuous physical activity from 48 hours prior to the 
first dose and during the study
[45] have an average weekly alcohol intake that exceeds 21 units per week (males) 
and 14 units per week (females), or are unwilling to stop alcohol consumption 
from 48 hours prior to Check-in and during the study (1 unit = 12 oz or 
360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits)
[46] are unwilling to refrain from consuming caffeine- or xanthine-containing food 
and drink within 48 hours prior to Check-in and while resident in the CRU
[47] in the opinion of the investigator or sponsor, are unsuitable for inclusion in the 
study
6.3.
Lifestyle and/or Dietary Requirements
Throughout the study, subjects may undergo medical assessments and review of compliance with 
requirements before continuing in the study.  
Meals and Dietary Restrictions
6.3.1.
Standardized meals will be provided during each subject’s stay in the CRU.
Subjects will be required to fast overnight (at least 8 hours) prior to study drug doses that are 
followed by PK sample collection (Period 1 Day 1 and Period 2 Days 7 and 8).  Fluids will be 
restricted from 1 hour prior to and until 1 hour after dosing with the exception of water required 


I8D-MC-AZEB(a) Clinical Pharmacology Protocol
Page 27
LY3314814
for study drug administration.  Water will be allowed ad libitum at all other times during the 
study.  A standard meal will be given to the subjects no sooner than 4 hours after dosing on 
Period 1 Day 1 and Period 2 Days 7 and 8.  On all other days when dosing is not followed by PK 
sample collection, study drug may be administered without regard to food and water.  Meals will 
be provided as appropriate at all other times.
Subjects will refrain from consuming grapefruits or grapefruit-containing products, Seville 
oranges or Seville orange-containing products, star fruits or star fruit-containing products, 
pomelo, or commercial apple juice or orange juice within 7 days prior to the first dose of any 
study drug until the final PK sample is collected.  If this situation arises, inclusion or ongoing 
participation of the subject may be at the discretion of the investigator, in consultation with the 
sponsor or designee.
Caffeine, Alcohol, and Tobacco
6.3.2.
Subjects will refrain from consuming caffeine- or xanthine-containing food and drinks within 
48 hours prior to Check-in.  Caffeine- or xanthine-containing food and drinks will not be allowed 
while subjects are resident at the CRU.
Alcohol will not be permitted from 48 hours prior to Check-in and during the study.
Smoking will not be permitted throughout the study.  Subjects will not have used any tobacco- or 
nicotine-containing products (including, but not limited to, cigarettes, pipes, cigars, chewing 
tobacco, nicotine patches, nicotine lozenges, or nicotine gum) within 3 months prior to Check-in 
and during the entire study.
Activity
6.3.3.
No strenuous exercise will be allowed for 48 hours prior to the first dose and during the study.
6.4.
Screen Failures
Individuals who do not meet the criteria for participation in this study (screen failure) will not be 
re-screened.


I8D-MC-AZEB(a) Clinical Pharmacology Protocol
Page 28
LY3314814
7. Treatment
7.1.
Treatment Administered
Table AZEB.2 shows the treatment regimens.
Tablets of LY3314814 and/or rosuvastatin will be administered orally with approximately 
240 mL of room temperature water in the morning in a sitting position.  Subjects will not be 
allowed to lie supine for 2 hours after dosing, unless clinically indicated or for study procedures.
Table AZEB.2.
Treatments Administered
Treatment Name
Rosuvastatin
LY3314814
Dosage Formulation
20-mg tablet
50-mg tablet
Dosage Level
20 mg
50 mg
Route of Administration
Oral
Oral
Dosing Instructions
1 tablet taken on Period 1 
Day 1 and Period 2 Day 8
1 tablet taken once daily on 
Period 2 Days 1 through 12
The investigator or designee is responsible for:

explaining the correct use of the investigational products to the site personnel, 

verifying that instructions are followed properly,

maintaining accurate records of investigational product dispensing and collection,

and returning all unused medication to Lilly or its designee at the end of the study.
Note: In some cases, sites may destroy the material if, during the investigative site selection, the 
evaluator has verified and documented that the site has appropriate facilities and written 
procedures to dispose of clinical trial materials.  
Packaging and Labeling
7.1.1.
Each LY3314814 tablet is oval, biconvex, plain, dark tan, and film-coated.  Tablets contain 
50 mg LY3314814 and excipients and are provided in high-density polyethylene bottles.
Each rosuvastatin tablet is round, biconvex, pink, coated, and debossed with “CRESTOR” and 
“20” on one side (Crestor Prescribing Information).  Tablets contain 20 mg rosuvastatin and 
excipients and are provided in bottles.
Clinical trial materials will be labeled according to the country’s regulatory requirements.
7.2.
Method of Treatment Assignment
This study is not randomized.  All subjects are to receive all treatments as described in 
Section 5.1.  


I8D-MC-AZEB(a) Clinical Pharmacology Protocol
Page 29
LY3314814
Selection and Timing of Doses
7.2.1.
Doses administered on the mornings of Period 1 Day 1 and Period 2 Days 7 and 8 will be 
preceded by an overnight fast of at least 8 hours and followed by a fast of at least 4 hours 
postdose.  See Section 6.3.1 for meal and dietary restrictions .  All doses will be administered at 
approximately the same times on each day.  The actual time of all dose administrations will be 
recorded in the subject’s electronic case report form (eCRF).
7.3.
Blinding
This is an open-label study.
7.4.
Dose Modification
Dose adjustments are not allowed for this study.
7.5.
Preparation/Handling/Storage/Accountability
Only participants enrolled in the study may receive investigational product and only authorized 
site staff may supply or administer study treatment. All study treatments should be stored in an
environmentally controlled and monitored (manual or automated) area in accordance with the 
labeled storage conditions with access limited to the investigator and authorized site staff.
The investigator, institution, or the head of the medical institution (where applicable) is 
responsible for study treatment accountability, reconciliation, and record maintenance ( such as
receipt, reconciliation, and final disposition records).
7.6.
Treatment Compliance
The investigational product will be administered at the clinical site, and documentation of 
treatment administration will occur at the site.
7.7.
Concomitant Therapy
Drugs that are known strong inducers or inhibitors of CYP3A, strong inhibitors of Pgp, or 
inducers or inhibitors of BCRP are specifically excluded.  Drugs or dietary supplements that may 
affect rosuvastatin are specifically excluded.  Additional drugs are to be avoided during the study 
unless required to treat an AE or for the treatment of an ongoing medical problem.
If the need for concomitant medication arises, inclusion or continuation of the subject may be at 
the discretion of the investigator after consultation with a Lilly clinical pharmacologist (CP) or 
clinical research physician (CRP).  Occasional acetaminophen (paracetamol) up to a 2-gram total
dose in a 24-hour period may be used at the discretion of the investigator.  Any additional 
medication used during the course of the study must be documented.
7.8.
Treatment after the End of the Study
Not applicable for this study.


I8D-MC-AZEB(a) Clinical Pharmacology Protocol
Page 30
LY3314814
8. Discontinuation Criteria
8.1.
Discontinuation from Study Treatment
Discontinuation of the investigational product for abnormal liver tests should be considered by 
the investigator when a subject meets one of the following conditions after consultation with the 
Lilly-designated medical monitor:

ALT or AST >5 times ULN

ALT or AST >3 times ULN along with one of the following criteria:
o
sustained for more than 2 weeks, or
o
total bilirubin level (TBL) >2 times ULN, or
o
prothrombin time >1.5 times ULN, or
o
the appearance of fatigue, nausea, vomiting, right upper-quadrant pain or 
tenderness, fever, rash, and/or eosinophilia (>5%)

Alkaline phosphatase (ALP) >3 times ULN

ALP >2.5 times ULN and TBL >2 times ULN

ALP >2.5 times ULN with the appearance of fatigue, nausea, vomiting, right quadrant 
pain or tenderness, fever, rash, and/or eosinophilia (>5%)
Subjects who discontinue treatment due to a hepatic event or abnormality of liver tests should 
have further clinical and laboratory monitoring and should have addition al data collected.  The 
process should be initiated by the investigator in consultation with the Lilly CRP/CP.
Subjects who discontinue the investigational product early will have early discontinuation
procedures performed as shown in the Schedule of Activities (Section 2).
Discontinuation of Inadvertently Enrolled Subjects
8.1.1.
If the sponsor or investigator identifies a subject who did not meet enrollment criteria and was 
inadvertently enrolled, a discussion must occur between the Lilly CP or CRP and the investigator 
to determine if the subject may continue in the study.  If both agree it is medically appropriate to 
continue, the investigator must obtain documented approval from the Lilly CP or CRP to allow 
the inadvertently enrolled subject to continue in the study with or without continued treatment 
with investigational product.
8.2.
Discontinuation from the Study
Subjects will be discontinued in the following circumstances:

enrollment in any other clinical trial involving an investigational product or enrollment in 
any other type of medical research judged not to be scientifically or medically compatible 
with this study


I8D-MC-AZEB(a) Clinical Pharmacology Protocol
Page 31
LY3314814

participation in the study needs to be stopped for medical, safety, regulatory, or other 
reasons consistent with applicable laws, regulations, and good clinical practice (GCP)

investigator decision
o
the investigator decides that the subject should be discontinued from the study

subject decision
o
the subject requests to be withdrawn from the study
Subjects who discontinue the study early will have early discontinuation procedures performed 
as shown in the Schedule of Activities (Section 2).
8.3.
Subjects Lost to Follow-up
A subject will be considered lost to follow-up if he or she repeatedly fails to return for scheduled 
visits and is unable to be contacted by the study site.  Site personnel are expected to make 
diligent attempts to contact subjects who fail to return for a scheduled visit or were otherwise 
unable to be followed up by the site.


I8D-MC-AZEB(a) Clinical Pharmacology Protocol
Page 32
LY3314814
9. Study Assessments and Procedures
Section 2 lists the Schedule of Activities, detailing the study procedures and their timing 
(including tolerance limits for timing).
Appendix 2 lists the clinical laboratory tests that will be performed for this study.
Appendix 5 provides a summary of the maximum number and volume of invasive samples, for 
all sampling, during the study.
Unless otherwise stated in subsections below, all samples collected for specified laboratory tests 
will be destroyed within 60 days of receipt of confirmed test results.  Certain samples may be 
retained for a longer period, if necessary, to comply with applicable laws, regulations, or 
laboratory certification standards.
Investigators must document their review of each laboratory safety report.
9.1.
Efficacy Assessments
This section is not applicable for this study.
9.2.
Adverse Events
Investigators are responsible for monitoring the safety of subjects who have entered this study 
and for alerting Lilly or its designee to any event that seems unusual, even if this event may be 
considered an unanticipated benefit to the subject.
The investigator is responsible for the appropriate medical care of subjects during the study.
The investigator remains responsible for following, through an appropriate health care option, 
AEs that are serious or otherwise medically important, considered related to the investigational 
product or the study, or that caused the subject to discontinue the investigational product before 
completing the study.  The subject should be followed until the event resolves, stabilizes with 
appropriate diagnostic evaluation, or is reasonably explained.  The frequency of follow-up 
evaluations of the AE is left to the discretion of the investigator.
After the informed consent form (ICF) is signed, study site personnel will record, via eCRF, the 
occurrence and nature of each subject’s preexisting conditions.  Additionally, site personnel will 
record any change in the condition(s) and the occurrence and nature of any AEs.  
Any clinically significant findings from ECGs, labs, vital sign measurements, and other 
procedures should be reported as an AE to Lilly or its designee.
The investigator will interpret and document whether or not an AE has a reasonable possibility 
of being related to study treatment or a study procedure, taking into account concomitant 
treatment or pathologies.  
A “reasonable possibility” means that there is a cause and effect relationship between the 
investigational product and/or study procedure and the AE.


I8D-MC-AZEB(a) Clinical Pharmacology Protocol
Page 33
LY3314814
Planned surgeries should not be reported as AEs unless the underlying medical condition has 
worsened during the course of the study.
If a subject’s investigational product is discontinued as a result of an AE, study site personnel 
must report this to Lilly or its designee via eCRF.
Serious Adverse Events
9.2.1.
An SAE is any AE from this study that results in one of the following:

death

initial or prolonged inpatient hospitalization

a life-threatening experience (that is, immediate risk of dying)

persistent or significant disability/incapacity

congenital anomaly/birth defect

events considered significant by the investigator based upon appropriate medical 
judgment
Study site personnel must alert Lilly, or its designee, of any SAE within 24 hours of investigator 
awareness of the event via a sponsor-approved method.  If alerts are issued via telephone, they 
are to be immediately followed with official notification on study-specific SAE forms.  This 
24-hour notification requirement refers to the initial SAE information and all follow -up SAE 
information.  
Although all AEs are recorded in the eCRF after signing informed consent, SAE reporting begins 
after the subject has signed informed consent and has received investigational product.  
However, if an SAE occurs after signing informed consent, but prior to receiving investigational 
product, AND is considered reasonably possibly related to a study procedure then it MUST be 
reported.
Investigators are not obligated to actively seek AEs or SAEs in subjects once they have 
discontinued from and/or completed the study (the subject summary eCRF has been completed).  
However, if the investigator learns of any SAE, including a death, at any time after a subject has 
been discharged from the study, and he/she considers the event reasonably possibly related to the 
study treatment or study participation, the investigator must promptly notify Lilly .  
Pregnancy (maternal or paternal exposure to investigational product) does not meet the definition 
of an AE.  However, to fulfill regulatory requirements, any pregnancy should be reported 
following the SAE process to collect data on the outcome for both mother and fetus.
9.2.1.1.
Suspected Unexpected Serious Adverse Reactions 
Suspected unexpected serious adverse reactions (SUSARs) are serious events that are not listed 
in the IB and that the investigator identifies as related to investigational product or procedure.  
United States 21 Code of Federal Regulations 312.32 and European Union Clinical 
Trial Directive 2001/20/EC and the associated detailed guidances or national regulatory 


I8D-MC-AZEB(a) Clinical Pharmacology Protocol
Page 34
LY3314814
requirements in participating countries require the reporting of SUSARs.  Lilly has procedures 
that will be followed for the recording and expedited reporting of SUSARs that are consistent 
with global regulations and the associated detailed guidances.
Complaint Handling
9.2.2.
Lilly will forward product complaints on LY3314814 to AstraZeneca in order to ensure the 
safety of study participants, monitor quality, and to facilitate process and product improvements.
Subjects should be instructed to contact the investigator as soon as possible if he or she has a 
complaint or problem with the investigational product so that the situation ca n be assessed.
Complaints related to concomitant drugs are reported directly to the manufacturers of those 
drugs in accordance with the package insert.
The investigator or his/her designee is responsible for handling the following aspects of the 
product complaint process in accordance with the instructions provided for this study:

recording a complete description of the product complaint reported and any associated 
AEs

communicating the product complaint within 24 hours to Lilly or its designee
If the investigator is asked to return the product for investigation, he/she will return a copy of the 
product complaint correspondence with the product.
9.3.
Treatment of Overdose
For the purposes of this study, an overdose of LY3314814 or rosuvastatin is considered any dose 
higher than the assigned dose.  There is no specific antidote for LY3314814.  There is no specific 
treatment in the event of rosuvastatin overdose.  In the event of an overdose, the subject should 
receive appropriate supportive care and any AEs should be documented.
Refer to the LY3314814 IB and Crestor Product Label for more information.
9.4.
Safety
Laboratory Tests
9.4.1.
For each subject, clinical laboratory tests detailed in Appendix 2 should be conducted according 
to the Schedule of Activities (Section 2).  
Vital Signs
9.4.2.
For each subject, vital signs measurements should be conducted according to the Schedule of 
Activities (Section 2).  
Supine blood pressure and pulse rate should be measured after at least 5 minutes supine rest.  
Following the respective supine vital signs measurement, subjects will sit for approximately 
1 minute and then standing blood pressure and pulse rate should be taken at 2 minutes, but no 
longer than 3 minutes, and at 5 minutes in a standing position.


I8D-MC-AZEB(a) Clinical Pharmacology Protocol
Page 35
LY3314814
If the subject feels unable to stand, supine and seated vital signs will be recorded.  
Unscheduled orthostatic vital signs should be assessed, if possible, during any AE of dizziness or 
posture-induced symptoms.  Additional vital signs may be measured during each study period if 
warranted and agreed upon between the sponsor and investigator.
Body temperature will be measured as specified in the Schedule of Activities (Section 2) and as 
clinically indicated.
Electrocardiograms
9.4.3.
For each subject, a single 12-lead digital ECG will be collected according to the Schedule of 
Activities (Section 2).  Electrocardiograms must be recorded before collecting any blood for 
safety or PK tests and before vital signs measurements.  Subjects must be supine for at least 
5 minutes before ECG collection and remain supine but awake during ECG collection.  
Electrocardiograms may be obtained at additional times, when deemed clinically necessary.  All 
ECGs recorded should be stored at the investigational site.
Electrocardiograms will be interpreted by a qualified investigator (or designee) at the site as soon 
after the time of ECG collection as possible, and ideally while the subject is still present, to 
determine whether the subject meets entry criteria at the relevant visit(s) and for immediate 
subject management, should any clinically relevant findings be identified.  
If a clinically significant finding is identified (including, but not limited to, changes in QT/QTc 
interval from baseline) after enrollment, the investigator will determine if the subject can 
continue in the study.  The investigator, or qualified designee, is responsible for determining if 
any change in subject management is needed, and must document his/her review of the ECG 
printed at the time of collection.  Any new clinically relevant finding should be reported to Lilly, 
or its designee, as an AE via eCRF.  
Physical Examination
9.4.4.
Physical examinations and routine medical assessments will be conducted as specified in the 
Schedule of Activities (Section 2) and as clinically indicated.
Body Weight
9.4.5.
Body weight will be recorded as specified in the Schedule of Activities (Section 2) and as 
clinically indicated.
Columbia-Suicide Severity Rating Scale
9.4.6.
The C-SSRS captures the occurrence, severity, and frequency of suicide-related thoughts and 
behaviors during the assessment period (Posner et al. 2007a, 2007b).  The scale includes 
suggested questions to solicit the type of information needed to determine if a suicide-related 
thought or behavior occurred.  Certified site personnel will administer the C-SSRS assessment 
and a corresponding self-harm supplement form as specified in the Schedule of Activities 
(Section 2) and as clinically indicated.  If a self-harm event is reported, investigators will also 
complete the “self-harm follow-up” form.  If the subject does not attend the discontinuation visit, 


I8D-MC-AZEB(a) Clinical Pharmacology Protocol
Page 36
LY3314814
the C-SSRS and “self-harm supplement” form should still be completed if the site has become 
aware of a suicide-related thought or behavior by other communications.  If a self-harm or 
suicidal-related event is considered serious by the investigator, it must be reported as an SAE via 
the procedures indicated in Section 9.2.1.  If a clinically significant finding is identified, the 
investigator will determine if the subject can continue in the study.  The investigator or qualified 
designee is responsible for determining if any change in subject management is needed.
Safety Monitoring
9.4.7.
The Lilly CP or CRP/scientist will monitor safety data throughout the course of the study.
Lilly will review SAEs within time frames mandated by company procedures.  The Lilly CP or 
CRP will consult with the functionally independent Global Patient Safety therapeutic area 
physician or clinical research scientist when appropriate, and periodically review:

trends in safety data

laboratory analytes 

AEs
If a study subject experiences elevated ALT ≥3 times ULN, ALP ≥2 times ULN, or elevated 
TBL ≥2 times ULN, liver testing (Appendix 4) should be repeated within 3 to 5 days to confirm 
abnormality.  If the abnormality persists or worsens, further clinical and laboratory monitoring 
should be initiated by the investigator in consultation with the Lilly-designated medical monitor.
In the event a subject experiences a suspected drug-induced rash, the following procedures 
should be followed:

The subject should be referred to a dermatologist for an expert opinion.

A photograph of the rash should be taken.

A blood sample should be drawn for PK analysis, if >12 hours since the last PK sample.
If treatment is discontinued due to a suspected drug-induced rash, the Lilly-designated medical 
monitor should be notified as soon as possible, even if the rash did not meet the definition of an 
SAE.
9.5.
Pharmacokinetics
At the visits and times specified in the Schedule of Activities (Section 2), venous blood samples 
of approximately 2 mL each will be collected to determine the plasma rosuvastatin 
concentrations and samples of approximately 2 mL each will be collected to determine the 
plasma LY3314814 concentrations.  A maximum of 3 samples may be collected at additional 
time points during the study if warranted and agreed upon between both the investigator and 
sponsor.  Instructions for the collection and handling of blood samples will be provided by the 
sponsor.  The actual date and 24-hour clock time of each sampling will be recorded.


I8D-MC-AZEB(a) Clinical Pharmacology Protocol
Page 37
LY3314814
Bioanalysis
9.5.1.
Samples will be analyzed at a laboratory approved by the sp onsor and stored at a facility 
designated by the sponsor.
Plasma rosuvastatin and LY3314814 concentrations will be assayed using validated liquid 
chromatography with tandem mass spectrometry method s.
Bioanalytical samples collected to measure investigational product concentrations will be 
retained for a maximum of 2 years following last subject visit for the study.  During this time, 
samples remaining after the bioanalyses may be used for exploratory analyses such as 
metabolism and/or protein binding work.
9.6.
Pharmacodynamics
Not applicable for this study.
9.7.
Genetics
A blood sample will be collected for pharmacogenetic analysis as specified in the Schedule of 
Activities (Section 2), where local regulations allow.  
Samples will not be used to conduct unspecified disease or population genetic research either 
now or in the future.  Samples will be used to investigate variable response to LY3314814 or 
rosuvastatin, and particularly to investigate the effect of polymorphisms on the disposition of 
LY3314814 and rosuvastatin. Samples may be used to investigate genetic variants thought to 
play a role in AD.  Assessment of variable response may include evaluation of AEs.  
All samples will be coded with the subject number.  These samples and any data generated can 
be linked back to the subject only by the investigative site personnel.  
Samples will be retained for a maximum of 15 years after the last subject visit, or for a shorter 
period if local regulations and/or ethical review boards (ERBs) impose shorter time limits, for 
the study at a facility selected by Lilly or its designee.  This retention period enables use of new 
technologies, response to regulatory questions, and investigation of variable response that may 
not be observed until later in the development of LY3314814 or after LY3314814 is 
commercially available.  
Molecular technologies are expected to improve during the 15-year storage period and therefore 
cannot be specifically named.  However, existing approaches include whole genome or exome 
sequencing, genome wide association studies, multiplex assays, and candidate gene studies.  
Regardless of technology utilized, data generated will be used only for the specific research 
scope described in this section.  
9.8.
Biomarkers
Biomarker research is performed to address questions of relevance to drug disposition, target 
engagement, pharmacodynamics, mechanism of action, variability of patient response (including 
safety), and clinical outcome.  Sample collection is incorporated into clinical studies to enable 


I8D-MC-AZEB(a) Clinical Pharmacology Protocol
Page 38
LY3314814
examination of these questions through measurement of biomolecules including DNA, RNA, 
proteins, lipids, and other cellular elements.  
Serum and plasma samples for non-pharmacogenetic biomarker research will be collected at the 
times specified in the Schedule of Activities (Section 2) where local regulations allow.
Samples will be used for research on the drug target, disease process, variable response to 
LY3314814 or rosuvastatin, pathways associated with neurological disease, mechanism of action 
of LY3314814 or rosuvastatin, identification of LY3314814 metabolites, and/or research 
method, or for validating diagnostic tools or assay(s) related to neurological disease.
All samples will be coded with the subject number.  These samples and any data generated can 
be linked back to the subject only by the investigative site personnel.  
Samples will be retained for a maximum of 15 years after the last subject visit, or for a shorter 
period if local regulations and/or ERBs impose shorter time limits, at a facility selected by Lilly 
or its designee.  This retention period enables use of new technologies, response to regulatory 
questions, and investigation of variable response that may not be observed until later in the 
development of LY3314814 or after LY3314814 is commercially available.
9.9.
Health Economics
This section is not applicable for this study.


I8D-MC-AZEB(a) Clinical Pharmacology Protocol
Page 39
LY3314814
10.
Statistical Considerations and Data Analysis
10.1. Sample Size Determination
Up to 42 subjects may be enrolled in order that 24 subjects complete the study.  
For rosuvastatin AUC, the intrasubject variability (coefficient of variation) was estimated to be 
25.5% by assuming intrasubject variability comprised half of the total variability of 51% (CDER 
2003); Martin et al. (2016) estimated the intrasubject variability of rosuvastatin AUC to be 21%.
A sample size of 24 subjects will provide 92.3% probability that the estimated AUC geometric 
mean ratio will be within 0.15 of the upper and lower bounds of the 90% confidence interval (CI)
in the log scale, which corresponds to approximately 0.162 in the natural scale. 
While this study is not powered for the Cmax geometric mean ratio to be within 0.15 of the upper 
and lower bounds of the 90% CI in the log scale, the Cmax power calculations are described here 
to give the expected results context. For rosuvastatin Cmax, the intrasubject variability was 
estimated to be 35.9% by assuming intrasubject variability comprised half of the total variability 
of 71.8% (CDER 2003); Martin et al. (2016) estimated the Cmax intrasubject variability of 
rosuvastatin to be 34%. A sample size of 24 subjects will provide 19.6% probability that the 
estimated Cmax geometric mean ratio will be within 0.15 of the upper and lower bounds of the 
90% CI in the log scale.
10.2. Populations for Analyses
Study Participant Disposition
10.2.1.
A detailed description of subject disposition will be provided at the end of the study.  All 
subjects who discontinue from the study will be identified, and the extent of their participation in 
the study will be reported.  If known, a reason for their discontinuation will be given.  
Study Participant Characteristics
10.2.2.
The subject’s age, sex, weight, height, BMI, race/sub-race, tobacco/nicotine habits, or other 
demographic characteristics will be recorded and may be used in the PK and safety analyses as 
quantitative or classification variables.
10.3. Statistical Analyses
Statistical analysis of this study will be the responsibility of Eli Lilly and Company or its 
designee.
Pharmacokinetic analyses will be conducted on the full analysis set.  This set includes all data 
from all subjects receiving at least one dose of the investigational product according to the 
treatment the subjects actually received.  If a subject has an AE of vomiting that occurs at or 
before 2 times median tmax then that subject may be excluded from the PK summary statistics 
and statistical analysis.  Safety analyses will be conducted for all enrolled subjects, whether or 
not they completed all protocol requirements.


I8D-MC-AZEB(a) Clinical Pharmacology Protocol
Page 40
LY3314814
Additional exploratory analyses of the data will be conducted as deemed appropriate.  Study 
results may be pooled with the results of other studies for population PK analysis purposes to 
avoid issues with post-hoc analyses and incomplete disclosures of analyses.  
Safety Analyses
10.3.1.
10.3.1.1. Clinical Evaluation of Safety
All investigational product and protocol procedure AEs will be listed and, if the frequency of 
events allows, safety data will be summarized using descriptive methodology.
The incidence of symptoms for each treatment will be presented by severity and by association 
with investigational product as perceived by the investigato r.  Symptoms reported to occur prior 
to enrollment will be distinguished from those reported as new or increased in severity during the 
study.  Each symptom will be classified by the most suitable term from the medical regulatory 
dictionary.
The number of investigational product-related SAEs will be reported.
10.3.1.2. Statistical Evaluation of Safety
Safety parameters that will be assessed include safety clinical lab parameters, vital signs, and 
C-SSRS.  Orthostatic changes in vital signs will be assessed using change from supine to 
standing.  The clinical lab parameters and C-SSRS data will be listed.  Vital signs will be listed 
and summarized using standard descriptive statistics.  Electrocardiograms will be performed for 
safety monitoring purposes and will not be presented.  Additional analysis may be performed if 
warranted upon review of the data.
Pharmacokinetic Analyses
10.3.2.
10.3.2.1. Pharmacokinetic Parameter Estimation
Pharmacokinetic parameter estimates for rosuvastatin and LY3314814 will be calculated by 
standard noncompartmental methods of analysis.   The primary PK parameter for analysis of 
rosuvastatin will be AUC(0-∞) following both doses.  The Cmax and tmax will also be reported. 
Other noncompartmental parameters, such as AUC from time zero to time tlast (AUC[0-tlast]), 
where tlast is the last time point with a measurable concentration;  t1/2; apparent clearance; and 
apparent volume of distribution, may be reported as appropriate.
The following PK parameters will be determined for LY3314814:  Cmax, tmax, and AUCτ.  Other 
noncompartmental parameters may be reported as appropriate.
10.3.2.2. Pharmacokinetic Statistical Inference
Rosuvastatin administered alone (Period 1 Day 1) will represent the reference treatment and 
rosuvastatin coadministered with LY3314814 will represent the test treatment (Period 2 Day 8) 
for rosuvastatin PK analysis.  Pharmacokinetic parameter estimates will be evaluated to delineate 
the effects of LY3314814 on rosuvastatin PK.
Log-transformed AUC(0-∞) and Cmax estimates for rosuvastatin will be analyzed using a linear 
mixed-effects analysis of variance model with treatment as a fixed effect and subject as a random 


I8D-MC-AZEB(a) Clinical Pharmacology Protocol
Page 41
LY3314814
effect.  The ratios of geometric least squares means (ie, rosuvastatin + LY3314814 to 
rosuvastatin alone) will be calculated along with the 90% CI for the ratios.  
The tmax for rosuvastatin will be analyzed using a nonparametric method; median differences of 
rosuvastatin + LY3314814 to rosuvastatin alone and the 90% CI for the median of differences 
will be calculated.
A similar analysis will be performed to evaluate the effect of rosuvastatin on LY3314814, where 
LY3314814 administered alone (Period 2 Day 7) will be the reference treatment and LY3314814 
coadministered with rosuvastatin will remain the test treatment (Period 2 Day 8).  
Additional analysis may be conducted if deemed appropriate.
The effect of polymorphisms in genes coding for certain transporters (eg, ABCG2, ABCB1, 
ABCC2, SLCO1B3, NTCP, and SLCO2B1) on the magnitude of the interaction between 
rosuvastatin and LY3314814 may be explored.  For each subject, the ratio of rosuvastatin 
exposures with and without concomitant LY3314814 exposures will be calculated.  A graphical 
analysis of these ratios between subjects with and without SNPs of interest is intended.  
Additional analyses may be conducted as warranted.
An exploratory assessment of the effect of genetic polymorphisms in transporter enzymes on 
rosuvastatin PK may be conducted.  The results of this study may be merged with the results of 
other studies of rosuvastatin to increase the likelihood of identifying the clinical significance of 
any particular polymorphism and reported elsewhere.  
Interim Analyses
10.3.3.
No interim analyses are planned for this study.  If an unplanned interim analysis is deemed 
necessary, the Lilly CP, CRP/investigator, or designee will consult with the appropriate medical 
director or designee to determine if it is necessary to amend the protocol.


I8D-MC-AZEB(a) Clinical Pharmacology Protocol
Page 42
LY3314814
11.
References
Center for Drug Evaluation and Research (CDER). Approval package for application number 
21-366 reviewed by Clinical Pharmacology and Biopharmaceutics Review. 2003. Available at: 
http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-366_Crestor_BioPharmr.pdf. 
Accessed August 17, 2016.
Chu X, Cai X, Cui D, Tang C, Ghosal A, Chan G, Green MD, Kuo Y, Liang Y, Maciolek CM, 
Palamanda J, Evers R, Prueksaritanont T. In vitro assessment of drug-drug interaction 
potential of boceprevir associated with drug metabolizing enzymes and transporters. Drug 
Metab Dispos. 2013;41(3):668-881.
Crestor (rosuvastatin calcium) Tablets [Prescribing Information]. Wilmington, DE: AstraZeneca 
Pharmaceuticals LP; 2003. Revised May 2016.
Crestor 5 mg, 10 mg, 20 mg and 40 mg film-coated tablets [Summary of Product 
Characteristics]. Luton, United Kingdom: AstraZeneca UK Limited; 2003. Revised March 
2016. Available at: http://www.medicines.org.uk/emc/document.aspx?documentid=11976. 
Accessed September 15, 2016.
Cusato J, Allegra S, Massano D, De Francia S, Piga A, D’Avolio A. Influence of 
single-nucleotide polymorphisms on deferasirox C trough levels and effectiveness. 
Pharmacogenomics J. 2015;15(3):263-271.
Elsby R, Martin P, Surry D, Sharma P, Fenner K. Solitary inhibition of the breast cancer 
resistance protein efflux transporter results in a clinically significant drug-drug interaction with 
rosuvastatin by causing up to a 2-fold increase in statin exposure. Drug Metab Dispos. 
2016;44(3):398-408.
Furukawa T1, Wakabayashi K, Tamura A, Nakagawa H, Morishima Y, Osawa Y, Ishikawa T. 
Major SNP (Q141K) variant of human ABC transporter ABCG2 undergoes lysosomal and 
proteasomal degradations. Pharm Res. 2009;26(2):469-479.
International Transporter Consortium, Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, 
Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa 
T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, 
Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L. Membrane transporters in drug 
development. Nat Rev Drug Discov. 2010;9(3):215-236.
Kim KA, Joo HJ, Park JY. ABCG2 polymorphisms, 34G>A and 421C>A in a Korean 
population: analysis and a comprehensive comparison with other populations. J Clin Pharm 
Ther. 2010;35(6):705-712.
Keskitalo JE, Zolk O, Fromm MF, Kurkinen KJ, Neuvonen PJ, Niemi M. ABCG2 
polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin 
Pharmacol Ther. 2009;86(2):197-203.
Lee CA, O'Connor MA, Ritchie TK, Galetin A, Cook JA, Ragueneau-Majlessi I, Ellens H, Feng 
B, Taub ME, Paine MF, Polli JW, Ware JA, Zamek-Gliszczynski MJ. Breast cancer resistance 
protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical 
recommendations for clinical victim and perpetrator drug-drug interaction study design. Drug 
Metab Dispos. 2015;43(4):490-509.


I8D-MC-AZEB(a) Clinical Pharmacology Protocol
Page 43
LY3314814
Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, van 
De Vijver MJ, Scheper RJ, Schellens JH. Subcellular localization and distribution of the breast 
cancer resistance protein transporter in normal human tissues. Cancer Res. 
2001;61(8):3458-3464.
Martin P, Gillen M, Ritter J, Mathews D, Brealey C, Surry D, Oliver S, Holmes V, Severin P, 
Elsby R. Effects of Fostamatinib on the Pharmacokinetics of Oral Contraceptive, Warfarin, 
and the Statins Rosuvastatin and Simvastatin: Results From Phase I Clinical Studies. 
Drugs R D. 2016;16(1):93-107.
Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1B1: A 
genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol 
Rev. 2011;63(1):157-181.
Pasanen MK1, Fredrikson H, Neuvonen PJ, Niemi M. Different effects of SLCO1B1 
polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther. 
2007;82(6):726-733.
Posner K, Melvin GA, Stanley B, Oquendo MA, Gould M. Factors in the assessment of 
suicidality in youth. CNS Spectr. 2007a;12(2):156-162.
Posner K, Oquendo MA, Gould M, Stanley B, Davies M. Columbia Classification Algorithm of 
Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal 
risk analysis of antidepressants. Am J Psychiatry. 2007b;164(7):1035-1043.
Wan Z, Wang G, Li T, Xu B, Pei Q, Peng Y, Sun H, Cheng L, Zeng Y, Yang G, Zhu YS.  
Marked Alteration of Rosuvastatin Pharmacokinetics in Healthy Chinese with ABCG2 34G>A 
and 421C>A Homozygote or Compound Heterozygote. J Pharmacol Exp Ther. 
2015;354(3):310-315.


I8D-MC-AZEB(a) Clinical Pharmacology Protocol
Page 44
LY3314814
Appendix 1.
Abbreviations and Definitions
Term
Definition
AD
Alzheimer’s disease
AE
adverse event:  Any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a causal 
relationship with this treatment.  An AE can therefore be any unfavorable and unintended 
sign (including an abnormal laboratory finding), symptom, or disease temporally associated 
with the use of a medicinal (investigational) product, whether or not related to the medicinal 
(investigational) product.
ALP
alkaline phosphatase
ALT
alanine aminotransferase
AST
aspartate aminotransferase
AUC
area under the drug concentration-time curve
AUCτ
area under the drug concentration-time curve during a 24-hour dosing interval
AUC(0-∞)
area under the drug concentration-time curve from zero to infinity
AUC(0-tlast)
area under the drug concentration-time curve from time zero to time tlast, where tlast is the 
last time point with a measurable concentration
AV
atrioventricular
BCRP
breast cancer resistance protein
BMI
body mass index
CI
confidence interval
Cmax
maximum observed drug concentration
complaint
A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.
compliance
Adherence to all the trial-related requirements, good clinical practice (GCP) requirements, 
and the applicable regulatory requirements.
confirmation
A process used to confirm that laboratory test results meet the quality requirements defined 
by the laboratory generating the data and that Lilly is confident that results are accurate.  
Confirmation will either occur immediately after initial testing or will require that samples 
be held to be retested at some defined time point, depending on the steps required to obtain 
confirmed results.


I8D-MC-AZEB(a) Clinical Pharmacology Protocol
Page 45
LY3314814
CP
clinical pharmacologist
CRP
clinical research physician:  Individual responsible for the medical conduct of the study.  
Responsibilities of the CRP may be performed by a physician, clinical research scientist, 
global safety physician or other medical officer.
CRU
clinical research unit
C-SSRS
Columbia-Suicide Severity Rating Scale
CYP
cytochrome P450
ECG
electrocardiogram
eCRF
electronic case report form
enroll
The act of assigning a subject to a treatment.  Subjects who are enrolled in the trial are those 
who have been assigned to a treatment.
enter
Subjects entered into a trial are those who sign the informed consent form directly or 
through their legally acceptable representatives.
ERB
ethical review board
GCP
good clinical practice
HIV
human immunodeficiency virus
IB
Investigator’s Brochure
IC50
concentration of drug causing half-maximal inhibitory effect
ICF
informed consent form
ICH
International Conference on Harmonization
informed consent
A process by which a subject voluntarily confirms his or her willingness to participate in a 
particular trial, after having been informed of all aspects of the trial that are relevant to the 
subject’s decision to participate.  Informed consent is documented by means of a written, 
signed and dated informed consent form.  
investigational 
product
A pharmaceutical form of an active ingredient or placebo being tested or used as a reference 
in a clinical trial, including products already on the market when used or assembled 
(formulated or packaged) in a way different from the authorized form, or marketed products 
used for an unauthorized indication, or marketed products used to gain further information 
about the authorized form.
investigator
A person responsible for the conduct of the clinical trial at a trial site.  If a trial is conducted 
by a team of individuals at a trial site, the investigator is the responsible leader of the team 
and may be called the principal investigator.
OATP
organic anion transporting polypeptide


I8D-MC-AZEB(a) Clinical Pharmacology Protocol
Page 46
LY3314814
open-label
A study in which there are no restrictions on knowledge of treatment allocation, therefore 
the investigator and the study participant are aware of the drug therapy received during the 
study.
Pgp
P-glycoprotein
PK
pharmacokinetic(s)
QD
once daily
SAE
serious adverse event
screen
The act of determining if an individual meets minimum requirements to become part of a 
pool of potential candidates for participation in a clinical trial.  
SNP
single nucleotide polymorphism
SUSARs
suspected unexpected serious adverse reactions 
t1/2
half-life associated with the terminal elimination phase
TBL
total bilirubin level
TEAE
treatment-emergent adverse event:  Any untoward medical occurrence that emerges during 
a defined treatment period, having been absent pretreatment, or worsens relative to the 
pretreatment state, and does not necessarily have to have a causal relationship with this 
treatment.  
tmax
time of maximum observed drug concentration
ULN
upper limit of normal


I8D-MC-AZEB(a) Clinical Pharmacology Protocol
Page 47
LY3314814
Appendix 2.
Clinical Laboratory Tests
Laboratory Tests
Hematologya
Clinical Chemistrya
Hematocrit
Sodium
Hemoglobin
Potassium
Erythrocyte count (RBC)
Bicarbonate
Mean cell volume 
Chloride
Mean cell hemoglobin 
Calcium
Mean cell hemoglobin concentration 
Glucose, random
Leukocytes (WBC)
Blood urea nitrogen
Cell Morphology
Total cholesterol
Absolute counts of:
Total protein
Neutrophils
Albumin
Lymphocytes
Total bilirubin
Monocytes
Alkaline phosphatase
Eosinophils
Aspartate aminotransferase
Basophils
Alanine aminotransferase
Platelets
Creatinine
Creatine phosphokinase
Urinalysisa
Specific gravity
Ethanol testingc
pH
Urine drug screenc
Protein
Hepatitis B surface antigend
Glucose
Hepatitis C antibodyd
Ketones
HIVd
Bilirubin
Pregnancy test (females)e
Urobilinogen
FSH (females, if applicable)d
Blood
OATP1B1, OATP521 T/TT, and BCRP genotypesf
Nitrite
Microscopic examination of sedimentb
Abbreviations:  BCRP = breast cancer resistance protein; FSH = follicle-stimulating hormone; HIV = human 
immunodeficiency virus; OATP = organic anion transporting polypeptide; RBC = red blood cells; WBC = white 
blood cells.
a
Performed by local laboratory.  Results will be validated by the laboratory at the time of initial testing.
b
Test only if dipstick result is abnormal (ie, positive for blood, protein, or nitrites).
c
Urine drug screen and ethanol testing will be performed by local laboratory at screening and at admission to the 
clinical research unit.
d
Performed by local laboratory at screening only.
e
Serum pregnancy tests will be performed at admission to the clinical research unit and at study follow-up or early 
termination.  Tests will be performed by local laboratory.
f
Performed by central laboratory.


I8D-MC-AZEB(a) Clinical Pharmacology Protocol
Page 48
LY3314814
Appendix 3.
Study Governance, Regulatory, and 
Ethical Considerations
Informed Consent
The investigator is responsible for:

ensuring that the subject understands the potential risks and benefits of participating in 
the study.

ensuring that informed consent is given by each subject or legal representative.  This 
includes obtaining the appropriate signatures and dates on the ICF prior to the 
performance of any protocol procedures and prior to the administration of investigational 
product.

answering any questions the subject may have throughout the study and sharing in a 
timely manner any new information that may be relevant to the subject ’s willingness to 
continue his or her participation in the trial.
Ethical Review
The investigator must give assurance that the ethical review board (ERB) was properly 
constituted and convened as required by International Conference on Harmonization (ICH)
guidelines and other applicable laws and regulations.
Documentation of ERB approval of the protocol and the ICF must be provided to Lilly before the 
study may begin at the investigative site(s).  Lilly or its representatives must approve the ICF 
before it is used at the investigative site(s).  All ICFs must be compliant with the ICH guideline 
on GCP.
The study site’s ERB(s) should be provided with the following:

the current IB and updates during the course of the study

ICF

relevant curricula vitae
Regulatory Considerations
This study will be conducted in accordance with:
1) consensus ethics principles derived from international ethics guidelines, 
including the Declaration of Helsinki and Council for International
Organizations of Medical Sciences International Ethical Guidelines 
2) applicable ICH GCP Guidelines 
3) applicable laws and regulations
Some of the obligations of the sponsor will be assigned to a third party organization.


I8D-MC-AZEB(a) Clinical Pharmacology Protocol
Page 49
LY3314814
Protocol Signatures
The sponsor’s responsible medical officer will approve the protocol, confirming that, to the best 
of his or her knowledge, the protocol accurately describes the planned design and conduct of the 
study.  
After reading the protocol, each principal investigator will sign the protocol signature page and 
send a copy of the signed page to a Lilly representative.
Final Report Signature
The investigator or designee will sign the clinical study report for this study, indicating 
agreement with the analyses, results, and conclusions of the report.
The sponsor’s responsible medical officer and statistician will sign/approve the final clinical 
study report for this study, confirming that, to the best of his or her knowledge, the report 
accurately describes the conduct and results of the study.
Data Quality Assurance
To ensure accurate, complete, and reliable data, Lilly or its representatives will do the following:

provide instructional material to the study sites, as appropriate.

provide training to instruct the investigators and study coordinators.  This training will 
give instruction on the protocol, the completion of the eCRFs, and study procedures.

make periodic visits to the study site.

be available for consultation and stay in contact with the study site personnel by mail, 
telephone, and/or fax.

review and evaluate eCRF data and/or use standard computer edits to detect errors in data 
collection.

conduct a quality review of the database.
In addition, Lilly or its representatives will periodically check a sample of the subject data 
recorded against source documents at the study site.  The study may be audited by Lilly and/or 
regulatory agencies at any time.  Investigators will be given notice before an audit occurs.
The investigator will keep records of all original source data.  This might include laboratory 
tests, medical records, and clinical notes.  If requested, the investigator will provide the sponsor, 
applicable regulatory agencies, and applicable ERBs with direct access to the original source 
documents.
Data Collection Tools/Source Data
An electronic data capture system will be used in this study.  The site must define and retain all 
source records and must maintain a record of any data where source data are directly entered into 
the data capture system.


I8D-MC-AZEB(a) Clinical Pharmacology Protocol
Page 50
LY3314814
Study and Site Closure
Discontinuation of Study Sites
Study site participation may be discontinued if Lilly or its designee, the investigator, or the ERB 
of the study site judges it necessary for medical, safety, regulatory, or other reasons consistent 
with applicable laws, regulations, and GCP.
Discontinuation of the Study
The study will be discontinued if Lilly or its designee judges it necessary for medical, safety, 
regulatory, or other reasons consistent with applicable laws, regulations, and GCP.


I8D-MC-AZEB(a) Clinical Pharmacology Protocol
Page 51
LY3314814
Appendix 4.
Hepatic Monitoring Tests for 
Treatment-Emergent Abnormality
Selected tests may be obtained in the event of a treatment-emergent hepatic abnormality and may 
be required in follow-up with subjects in consultation with Lilly or its designee clinical research 
physician.
Hepatic Monitoring Tests
Hepatic Hematologya
Haptoglobina
Hemoglobin
Hematocrit
Hepatic Coagulationa
RBC
Prothrombin Time
WBC
Prothrombin Time, INR
Neutrophils, segmented
Lymphocytes
Hepatic Serologiesa,b
Monocytes
Hepatitis A antibody, total
Eosinophils
Hepatitis A antibody, IgM
Basophils
Hepatitis B surface antigen
Platelets
Hepatitis B surface antibody
Hepatitis B Core antibody
Hepatic Chemistrya
Hepatitis C antibody
Total bilirubin
Hepatitis E antibody, IgG
Conjugated bilirubin
Hepatitis E antibody, IgM
Alkaline phosphatase
ALT
Anti-nuclear antibodya
AST
GGT
CPK 
Anti-smooth muscle antibody (or anti-actin 
antibody)a
Abbreviations:  ALT = alanine aminotransferase; AST = aspirate aminotransferase; CPK = creatine phosphokinase; 
GGT = gamma-glutamyl transferase; Ig = immunoglobulin; INR = international normalized ratio; RBC = red 
blood cells; WBC = white blood cells.
a
Assayed by local laboratory.
b
Reflex/confirmation dependent on regulatory requirements and/or testing availability.


I8D-MC-AZEB(a) Clinical Pharmacology Protocol
Page 52
LY3314814
Appendix 5.
Blood Sampling Summary
This table summarizes the approximate number of venipunctures and blood volumes for all 
blood sampling (screening, safety laboratories, and bioanalytical assays) during the study.  Fewer 
venipunctures and blood draws may actually occur, but this will not require a protocol 
amendment.
Protocol I8D-MC-AZEB Sampling Summary
Purpose
Maximum Blood Volume 
per Sample (mL)
Maximum Number 
of Blood Samples
Maximum Total 
Volume (mL)
Screening testsa
19.5
1
19.5
OATP1B1, OATP521 T/TT, and 
BCRP genotyping
10
1
10
Clinical laboratory testsa
12.5
5
62.5
Rosuvastatin pharmacokineticsb
2
31
62
LY3314814 pharmacokineticsb
2
20
40
Pharmacogenetics
10
1
10
Biomarker analysis
10
28
280
Total
484
Total for clinical purposes rounded up to nearest 10 mL
490
Abbreviations:  BCRP = breast cancer resistance protein; OATP = organic anion transporting polypeptide.
a
Additional samples may be drawn if needed for safety purposes.
b
Including the 3 additional pharmacokinetic samples, if needed.


I8D-MC-AZEB(a) Clinical Pharmacology Protocol
Page 53
LY3314814
Appendix 6.
Protocol Amendment I8D-MC-AZEB(a) 
Summary
Effect of LY3314814 on the Pharmacokinetics of 
Rosuvastatin in Caucasian Healthy Subjects
Overview
Protocol I8D-MC-AZEB “Effect of LY3314814 on the Pharmacokinetics of Rosuvastatin in 
Caucasian Healthy Subjects” has been amended.  The new protocol is indicated by Amendment 
(a) and will be used to conduct the study in place of any preceding version of the protocol.
The overall change and rationale for the change made to this protocol is as follows:

The total sample size has been increased by 14 subjects to ensure that 24 subjects can 
complete the study.  This increase takes into account the unanticipated withdrawal of 
10 subjects and allowance for any additional withdrawals.  The 10 subjects were 
withdrawn from the study early due to central laboratory errors in the genotyping results.  
Following enrollment based on the initial genotyping report, it was later determined the 
subjects did not meet the entry criteria based on the qualifying inclusive genotyping 
results reported.

The wording in Section 9.4.2 (Vital Signs) has been updated to clarify the time spent in a 
standing position after which standing blood pressure and pulse rate should be measured 
for determining orthostatic changes.

The wording in Section 6 has been updated to clarify that the genotyping does not need to 
be repeated for subjects who have other assessments repeated because they fall outside 
the 45-day screening window.


I8D-MC-AZEB(a) Clinical Pharmacology Protocol
Page 54
LY3314814
Revised Protocol Sections
Note:
All deletions have been identified by strikethroughs.
All additions have been identified by the use of underscore.
1.
Protocol Synopsis
Number of Subjects:  
Up to 28 42 subjects may be enrolled in order that 24 subjects complete the study.
5.2.
Number of Participants
Up to 28 42 subjects may be enrolled so that approximately 24 subjects complete the study.
6.
Study Population
[…]
Screening may occur up to 45 days prior to enrollment.  Subjects who are not enrolled within 
45 days of screening may be subjected to an additional medical assessment and/or clinical 
measurements to confirm their eligibility.  Subjects who meet all other screening eligibility 
criteria will return for a second screening visit, at least 21 days prior to enrollment, when 
samples will be collected for genotype analysis.  Genotyping only needs to be conducted once, 
regardless of the 45-day screening window and any repeated assessments to confirm eligibility.
9.4.2. Vital Signs
[…]
Supine blood pressure and pulse rate should be measured after at least 5 minutes supine rest.  
Following the respective supine vital signs measurement, subjects will sit for approximately 
1 minute and then standing blood pressure and pulse rate should be taken after at 2 minutes, but 
no longer than 3 minutes, and at 5 minutes in a standing position.
10.1.
Sample Size Determination
Up to 28 42 subjects may be enrolled in order that 24 subjects complete the study.  


Leo Document ID = f7a0c91a-617b-477c-bcd0-ebe7774d07ee
Approver: Scott W Andersen (AM\RM82091)
Approval Date & Time: 14-Mar-2017 15:49:13 GMT
Signature meaning: Approved
Approver: Juliet McColm (EMA\YE91063)
Approval Date & Time: 15-Mar-2017 09:01:29 GMT
Signature meaning: Approved

SAP_000.pdf: